Lateral Epicondylitis (Tennis Elbow) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Lateral Epicondylitis (Tennis Elbow) Market Outlook
Thelansis’s “Lateral Epicondylitis
(Tennis Elbow) Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2024 To 2034" covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Lateral Epicondylitis (Tennis
Elbow) treatment modalities options for eight major markets (USA, Germany,
France, Italy, Spain, UK, Japan, and China).
Lateral Epicondylitis (Tennis Elbow)
Overview
Lateral
epicondylitis, also known as Tennis elbow, is an injury caused by an eccentric
overload of the common extensor tendon at the extensor carpi radialis brevis
(ECRB) tendon’s origin. The main cause of tennis elbow is repetitive strain
brought on by holding something repeatedly and extending the wrist. People who
play badminton, squash, tennis, or any other activity requiring repetitive
wrist extension, radial deviation, and forearm supination are prone to it.
Tennis elbow is frequently an overuse injury caused mostly by repetitive strain
from holding objects repeatedly or extending the wrist. The main cause of this
illness is a degenerative process brought on by overuse of the common extensor
tendon and the extensor carpi radialis brevis. Imaging is frequently not
required for the clinical diagnosis of lateral epicondylitis. If the history
and physical examination point to other injuries or conditions, the provider
may consider ordering an elbow radiography series (anteroposterior and lateral).
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment